July 2026
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Jeff Schaffnit: Sanofi Highlights Progress in Hemophilia and ITP at ISTH 2026

Jeff Schaffnit/LinkedIn

Jul 15, 2026, 15:28

Jeff Schaffnit: Sanofi Highlights Progress in Hemophilia and ITP at ISTH 2026

Jeff Schaffnit, General Manager and Head of Rare Blood Disorders at Sanofi, shared a post on LinkedIn:

“Looking back on the last few days, it’s clear that this year’s ISTH 2026 marked not only an important moment to reflect on the progress being made across rare blood disorders but also a time to reinforce the collective commitment driving innovation forward for patients.

I’m proud of the momentum Sanofi continues to build across our Rare Blood Disorders portfolio, from advances in hemophilia to continued progress in Immune Thrombocytopenia (ITP), where ongoing research is reshaping how we think about disease control.

What stands out most to me is what these milestones represent: years of collaboration among researchers, clinicians, patient communities and teams across Sanofi, all working toward the same goal of improving the day-to-day lives of people living with rare blood disorders.

Thank you to everyone whose dedication to chasing the miracles of science continues to turn scientific progress into meaningful impact for patients and families.”

Jeff Schaffnit: Sanofi Highlights Progress in Hemophilia and ITP at ISTH 2026